Literature DB >> 14551205

Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B.

Aristotelis Astrinidis1, William Senapedis, Thomas R Coleman, Elizabeth Petri Henske.   

Abstract

Tuberous sclerosis complex is a tumor suppressor gene syndrome whose manifestations can include seizures, mental retardation, and benign tumors of the brain, skin, heart, and kidneys. Hamartin and tuberin, the products of the TSC1 and TSC2 genes, respectively, form a complex and inhibit signaling by the mammalian target of rapamycin. Here, we demonstrate that endogenous hamartin is threonine-phosphorylated during nocodazole-induced G2/M arrest and during the G2/M phase of a normal cell cycle. In vitro assays showed that cyclin-dependent kinase 1 phosphorylates hamartin at three sites, one of which (Thr417) is in the hamartin-tuberin interaction domain. Tuberin interacts with phosphohamartin, and tuberin expression attenuates the phosphorylation of exogenous hamartin. Hamartin with alanine mutations in the three cyclin-dependent kinase 1 phosphorylation sites increased the inhibition of p70S6 kinase by the hamartin-tuberin complex. These findings support a model in which phosphorylation of hamartin regulates the function of the hamartin-tuberin complex during the G2/M phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551205     DOI: 10.1074/jbc.M303956200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

Review 2.  The neurobiology of the tuberous sclerosis complex.

Authors:  Leah Marcotte; Peter B Crino
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

3.  Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1.

Authors:  Wen Song; Cuiping Guo; Jianxiong Chen; Shiyu Duan; Yukun Hu; Ying Zou; Honggang Chi; Jian Geng; Jun Zhou
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-20

4.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.

Authors:  Andrey Parkhitko; Faina Myachina; Tasha A Morrison; Khadijah M Hindi; Neil Auricchio; Magdalena Karbowniczek; J Julia Wu; Toren Finkel; David J Kwiatkowski; Jane J Yu; Elizabeth Petri Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

Review 5.  The tuberous sclerosis complex.

Authors:  Ksenia A Orlova; Peter B Crino
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

6.  Combination of chemical genetics and phosphoproteomics for kinase signaling analysis enables confident identification of cellular downstream targets.

Authors:  Felix S Oppermann; Kathrin Grundner-Culemann; Chanchal Kumar; Oliver J Gruss; Prasad V Jallepalli; Henrik Daub
Journal:  Mol Cell Proteomics       Date:  2011-12-22       Impact factor: 5.911

7.  Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.

Authors:  Zhiguo Li; Yifan Kong; Longzhen Song; Qian Luo; Jinghui Liu; Chen Shao; Xianzeng Hou; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

8.  Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle.

Authors:  Margit Rosner; Katharina Schipany; Markus Hengstschläger
Journal:  Nat Protoc       Date:  2013-02-28       Impact factor: 13.491

Review 9.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.